P62-DNA-encoding plasmid reverts tumor grade, changes tumor stroma, and enhances anticancer immunity.

ABSTRACT: Previously, we reported that the administration of a p62/SQSTM1-encoding plasmid demonstrates high safety and signs of clinical benefits for human cancer patients. The treatment also suppressed tumor growth and metastasis in dogs and mouse models. Here we investigated some mechanistic aspects of these effects. In mammary tumors bearing-dogs, i.m. injections of p62 plasmid reduced tumor sizes and their aggressive potential in 5 out of 6 animals, with one carcinoma switching to adenoma. The treatment increased levels of smooth muscle actin in stroma cells and type III collagen in the extracellular matrix, which correlate with a good clinical prognosis. The p62 treatment also increased the abundance of intratumoral T-cells. Because of the role of adaptive immunity cannot be tested in dogs, we

SUBMITTER: Venanzi FM 

PROVIDER: S-EPMC6914433 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature